Skip to Main Content

Drug Targeted Alerts for Acute Kidney Injury Amelioration (ELAIA-2)

This trial will randomize patients with acute kidney injury (AKI) who are receiving a kidney-toxic medication to alerts (highlighting the particular medication) versus usual care.


  • Associate Professor of Medicine (Nephrology) and Public Health (Chronic Disease Epidemiology); Director, Clinical and Translational Research Accelerator (CTRA); Course Director, Interpretation of the Medical Literature; Co Director, Human Genetics and Clinical Research Core


Aditya Biswas
Research Assistant, Yale University

Amit Garg, MD, PhD
Professor of Medicine (Nephrology), Western University, London, Ontario, Canada

Stephen Latham, JD, PhD
Director, Interdisciplinary Center for Bioethics, Yale University

Melissa Martin
Research Associate, Yale University

Paul M. Palevsky, MD
Professor of Medicine, Renal-Electrolyte Division, University of Pittsburgh

Chirag R. Parikh, MD, PhD
Adjunct Professor of Medicine, Yale University

Yu Yamamoto
Statistician, Yale University